Patents by Inventor Weiwen Ying

Weiwen Ying has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124460
    Abstract: Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 18, 2024
    Inventors: Weiwen Ying, Kevin P. Foley, Wei Yin, Long Ye, Mingkai Wang, Chenghao Ying, Lingjie Zhang
  • Publication number: 20240116950
    Abstract: Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 11, 2024
    Inventors: Weiwen Ying, Chenghao Ying, Kevin P. Foley, Zhiyong Wang, Wei Yin, Liang Ma, Guoqiang Wang, Jinhua Li, Yaya Wang, Yan Dai, Thomas Prince
  • Publication number: 20230391792
    Abstract: Provided are compounds of Formula: H-L-T and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: October 14, 2021
    Publication date: December 7, 2023
    Inventors: Weiwen Ying, Kevin P. Foley, Long Ye, Mingkai Wang, Chenghao Ying, Wei Yin, Lingjie Zhang
  • Publication number: 20230391772
    Abstract: Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: October 13, 2021
    Publication date: December 7, 2023
    Inventors: Weiwen Ying, Kevin P. Foley, Mingkai Wang, Chenghao Ying, Long Ye, Wei Yin, Lingjie Zhang
  • Publication number: 20230365595
    Abstract: Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula: R00F2C—L—R0 and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 16, 2023
    Applicant: Ranok Therapeutics (Hangzhou) Co. Ltd.
    Inventors: Weiwen Ying, Kevin P. Foley, Chenghao Ying, Zhiyong Wang, Wei Yin, Yaya Wang, Yan Dai, Thomas Prince
  • Publication number: 20230046803
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: September 27, 2022
    Publication date: February 16, 2023
    Inventors: Weiwen Ying, Dinesh U. Chimmanamada, David Proia
  • Patent number: 11491145
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: November 8, 2022
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Weiwen Ying, Dinesh U. Chimmanamada, David Proia
  • Publication number: 20220289749
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 15, 2022
    Inventors: Neera Jain, Weiwen Ying, Dinesh U. Chimmanamada, Junyi Zhang, Amit Kale
  • Patent number: 11377447
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: July 5, 2022
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Neera Jain, Weiwen Ying, Dinesh U. Chimmanamada, Junyi Zhang, Amit Kale
  • Publication number: 20220168427
    Abstract: Provided herein are methods and compositions for targeted protein degradation. In one aspect, a protein degradation chimera is provided, comprising: a first moiety that is capable of binding to a chaperone complex component; a second moiety that is capable of binding to a target protein or proteins, wherein the target protein (s) is targeted for degradation; and a tether configured to covalently couple the first moiety and the second moiety.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 2, 2022
    Inventors: Weiwen Ying, Long Ye, Kevin Foley
  • Publication number: 20220162228
    Abstract: Provided are compounds of Formula I: (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: April 8, 2020
    Publication date: May 26, 2022
    Inventors: Weiwen Ying, Long Ye, Kevin Foley
  • Publication number: 20210085700
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • Patent number: 10828315
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: November 10, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • Publication number: 20200316090
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: May 26, 2020
    Publication date: October 8, 2020
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20200239472
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 30, 2020
    Inventors: Neera Jain, Weiwen Ying, Dinesh U. Chimmanamada, Junyi Zhang, Amit Kale
  • Patent number: 10722525
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: July 28, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20200222374
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 16, 2020
    Inventors: Weiwen Ying, Dinesh U. Chimmanamada, David Proia
  • Patent number: 10675360
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: June 9, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20190314528
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Patent number: 10376598
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 13, 2019
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying